SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION																	
						Washington, D.C. 20549									OME		DVAL
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).					ed pur	suant	to Section	n 16(a	ES IN B a) of the Sec Investment	curitie	es Exchan		Estimated		lumber: ted average bur per response:	3235-0287 len 0.5	
1. Name and Address of Reporting Person [*] <u>Goldberg Mark Alan</u>						2. Issuer Name and Ticker or Trading Symbol ImmunoGen, Inc. [IMGN]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner			
(Last) (First) (Middle) C/O IMMUNOGEN, INC.						3. Date of Earliest Transaction (Month/Day/Year) 06/15/2022								Officer (give title Other (specify below) below)			
830 WINTER STREET					4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)			
(Street) WALTHAM MA 02451														X Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City) (State) (Zip)																	
		Tab	ole I - Nor	n-Deriv	/ativ	e Se	curities	s Ac	quired, [Disp	osed o	f, or Be	neficial	ly Owned			
1. Title of Security (Instr. 3) 2. Transa Date (Month/D					Execution Da			Code (Inst					Beneficia	es Form ally (D) c following (I) (II	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code	v	Amount	(A) o (D)	r Price	Transact (Instr. 3 a	ion(s)		(1130.4)
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)			3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	Ownersh Form: Direct (D or Indire (I) (Instr.	Beneficial Ownership t (Instr. 4)
					Code	v	(A)	(D)	Date Exercisable		xpiration ate	Title	Amount or Number of Shares				
Deferred Share Unit	\$0 ⁽¹⁾	06/15/2022			Α		15,000		(2)(3)		(3)	Common Stock ⁽³⁾	15,000	\$0 ⁽¹⁾	149,668	B D	
Stock Option (right to buy)	\$3.37	06/15/2022			Α		44,000		(4)	06	6/15/2032	Common Stock	44,000	\$3.37	44,000	D	

Explanation of Responses:

1. The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis.

2. The deferred share units vest ratably over a one-year period in quarterly increments beginning on 9/1/22, contingent upon the individual remaining a director as of each vesting date.

3. The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors.

4. Exercisable as to 11,000 shares on each of 9/1/22, 12/1/22, 3/1/23, and 6/1/23, contingent upon the individual remaining a director as of each vesting date.

/s/ Renee Lentini, Attorney-in-Fact 06/17/2022

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.